Here's Why Myriad Genetics Is Tumbling Today
Coronavirus testing is up, but the pandemic has hammered demand for Myriad's hereditary cancer tests.
Myriad Genetics
MYGN
MYGN
$11.47
$0.03
0.3%
Price as of July 10, 2020, 4:30 p.m. EDT
View Interactive MYGN Charts
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
Interactive Chart
News & Analysis: Myriad Genetics
The Fool has written over 200 articles on Myriad Genetics.
Myriad Genetics Inc (MYGN) Q3 2020 Earnings Call Transcript
MYGN earnings call for the period ending March 31, 2020.
Genetic Testing Stocks Rise Again as Volatility Continues
Have these growth stocks bottomed out? That's probably the wrong question to ask.
Should You Buy These 2 Prenatal Testing Stocks?
More babies are born in summer and early fall than other times of year, meaning mothers-to-be are likely undergoing prenatal testing now. Can investors profit?
Myriad Genetics CEO Mark Capone Resigns
The molecular diagnostics company also delivered an earnings miss, and its stock plunged.
Why Myriad Genetics Shares Are Tanking Today
The molecular diagnostics company's latest quarterly results weren't anywhere close to what Wall Street expected.
Myriad Genetics Inc (MYGN) Q2 2020 Earnings Call Transcript
MYGN earnings call for the period ending December 31, 2019.
Why Shake Shack, Myriad Genetics, and Trivago Slumped Today
Poor earnings took many stocks lower Tuesday.
Here's Why Myriad Genetics Shares Got Crushed Today
The genetic-testing leader just whacked its fiscal full-year 2020 guidance.
What's Behind Myriad Genetics' Disastrous Q1 Performance
Hardly anything went right for the genetic testing company in its fiscal 2020 Q1.
